Study guide

5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components

Key Takeaways Explain This Topic AI

Category 2 CSPs must be compounded in an ISO Class 5 PEC located within an ISO Class 7 buffer room with an ISO Class 7 or 8 ante-room.

For aseptically prepared Category 2 CSPs using sterile starting components without sterility testing: BUD is 4 days at controlled room temperature, 10 days refrigerated, and 45 days frozen.

For aseptically prepared Category 2 CSPs using one or more nonsterile starting components without sterility testing: BUD is 1 day (24 hours) at room temperature, 4 days refrigerated, and 45 days frozen.

For terminally sterilized Category 2 CSPs without sterility testing: BUD is 14 days at room temperature, 28 days refrigerated, and 45 days frozen.

With passing USP <71> sterility testing, Category 2 BUDs can be extended up to 30 to 45 days at room temperature, 45 to 60 days refrigerated, and 60 to 90 days frozen.

Last updated: September 2026

Architectural Mandates for Category 2 Compounding

To qualify for Category 2 Beyond-Use Dating , preparations must be compounded within a fully classified cleanroom suite :

Primary Engineering Control : An ISO Class 5 PEC (LAFW, Class II BSC, CAI, or CACI).

Secondary Engineering Control : An ISO Class 7 buffer room .

Ante-Room : An ISO Class 8 ante-room (for positive-pressure suites) or an ISO Class 7 ante-room (for negative-pressure hazardous drug suites).

Compounding personnel must satisfy initial 3-trial gloved fingertip testing with zero CFUs and semiannual competency re-qualifications.

The USP <797> 2023 Category 2 Default BUD Matrix

Under the 2023 revision of USP <797>, Category 2 BUDs are assigned based on three critical variables: starting component sterility , sterilization method , and sterility testing status .

Comprehensive Category 2 BUD Table

Preparation Method & Starting Materials Sterility Testing (USP <71>) Controlled Room Temp ( 20 ∘ C 20^\circ\text{C} 2 0 ∘ C to 25 ∘ C 25^\circ\text{C} 2 5 ∘ C ) Refrigerated ( 2 ∘ C 2^\circ\text{C} 2 ∘ C to 8 ∘ C 8^\circ\text{C} 8 ∘ C ) Frozen ( − 25 ∘ C -25^\circ\text{C} − 2 5 ∘ C to − 10 ∘ C -10^\circ\text{C} − 1 0 ∘ C )

  • Aseptically processed; sterile starting components only NO 4 days (96 hours) 10 days 45 days
  • Aseptically processed; ≥ 1 \ge 1 ≥ 1 nonsterile starting component NO 1 day (24 hours) 4 days 45 days
  • Terminally sterilized (autoclave/dry heat) NO 14 days 28 days 45 days
  • Aseptically processed (sterile components) YES (Passed) 30 days 45 days 60 days
  • Aseptically processed (nonsterile components) YES (Passed) 30 days 45 days 60 days
  • Terminally sterilized YES (Passed) 45 days 60 days 90 days

Note

Notice the pattern: frozen storage for all untested Category 2 CSPs is 45 days . Furthermore, passing USP <71> sterility testing extends refrigerated dating from 10 days to 45 days for aseptically processed sterile components, and up to 60 days for terminally sterilized preparations.

  • Analysis of Component Sterility & Sterilization Impact
  • 1. Sterile vs. Nonsterile Starting Components

When an active pharmaceutical ingredient (API) is introduced as a bulk nonsterile powder (e.g., baclofen powder for intrathecal pump compounding, or alum powder for bladder irrigation), bioburden may be high. Even if the solution is then sterilized by 0.22-micron filtration, USP <797> limits the untested BUD to 1 day at room temperature or 4 days refrigerated . Nonsterile components bring bioburden and bacterial endotoxin risk, and the CSP's sterility has not been confirmed by testing.

2. Terminal Sterilization vs. Aseptic Processing

Terminal sterilization, such as steam under pressure (USP <797> gives 20 to 60 minutes at 121 ∘ C 121^\circ\text{C} 12 1 ∘ C and 15 psi as an example, depending on load), destroys microorganisms inside the sealed final container, achieving a Sterility Assurance Level (SAL) of 10 − 6 10^{-6} 1 0 − 6 (less than one non-sterile unit per million). Because terminal sterilization is fundamentally more robust than aseptic assembly, untested terminally sterilized CSPs receive 14 days room temperature and 28 days refrigerated BUD allowances.

3. Stability Limitations

Regardless of the table values above, the BUD may never exceed what stability supports . The Table 13 limits are microbiological ceilings. USP <797> also requires the BUD to reflect chemical and physical stability, the container-closure system, and the shortest expiration of any component. Ampicillin is a classic example: its solutions hydrolyze within hours at room temperature, so the product labeling or a stability study, not Table 13, sets its BUD.

4. Sterility Testing Protocol & Quarantine Requirements

The longer Category 2 BUDs require a passing sterility test by USP <71> or a validated alternative that is non-inferior to it (USP <1223>). USP <71> incubates for 14 days, in Soybean-Casein Digest Medium at 20 ∘ C to 25 ∘ C 20^\circ\text{C to }25^\circ\text{C} 2 0 ∘ C to 2 5 ∘ C and Fluid Thioglycollate Medium at 30 ∘ C to 35 ∘ C 30^\circ\text{C to }35^\circ\text{C} 3 0 ∘ C to 3 5 ∘ C . USP <797> allows a CSP to be dispensed before release test results are known. In that case the facility must have procedures ready to notify the prescriber immediately of a failure, recall unused CSPs, quarantine remaining stock, and check other lots (USP <797> 18.1). Many facilities hold batches until results are final whenever the clinical schedule allows.

Sterilization Modalities for Nonsterile Preparations

When nonsterile starting components are utilized in Category 2 compounding, sterilization is legally and clinically mandatory. USP General Chapter <797> recognizes three primary sterilization modalities:

1. Sterilizing-Grade Membrane Filtration

Mechanics and Membrane Pore Size : Solutions must be passed through a certified sterilizing-grade hydrophilic membrane filter with a nominal pore rating of 0.22 μ m 0.22\,\mu\text{m} 0.22 μ m or 0.2 μ m 0.2\,\mu\text{m} 0.2 μ m , certified to retain ≥ 10 7 CFU / cm 2 \ge 10^7\,\text{CFU}/\text{cm}^2 ≥ 1 0 7 CFU / cm 2 of Brevundimonas diminuta (ATCC 19146).

Polymer Compatibility : Polyethersulfone (PES) is preferred for aqueous solutions and low protein binding; PVDF for biologics; PTFE for harsh organic solvents; and nylon for general aqueous compounding.

Mandatory Filter Integrity Testing : Each sterilizing filter must pass the manufacturer's recommended integrity test, such as a post-use bubble point test. The bubble point pressure follows the Young-Laplace relationship ( P = 4 γ cos ⁡ θ d P = \frac{4 \gamma \cos \theta}{d} P = d 4 γ c o s θ ​ ). If the filter fails, USP <797> requires the CSP to be discarded or, after the cause is investigated and a suitable filter chosen, refiltered no more than one additional time .

2. Moist Heat Sterilization (Steam Autoclaving)

Mechanics : Destroys microorganisms by denaturing and coagulating essential proteins. USP <797> cites 20 to 60 minutes at 121 ∘ C 121^\circ\text{C} 12 1 ∘ C and 15 psi 15\,\text{psi} 15 psi as an example; the actual time depends on container volume and load. Solutions are passed through a filter of 1.2 µm or smaller before filling, to remove particles.

Biological Validation : The effectiveness of every run or load is verified with appropriate biological indicators, such as Geobacillus stearothermophilus spores, read according to the indicator manufacturer's instructions. Physicochemical indicators support this, and a calibrated recorder documents each cycle.

3. Dry Heat Sterilization & Depyrogenation

Sterilization : Used for heat-stable, moisture-sensitive items such as oils and dry powders, usually in an oven at 160 ∘ C 160^\circ\text{C} 16 0 ∘ C or higher . Lower temperatures must be shown to be effective. Each run is verified with Bacillus atrophaeus biological indicators.

Depyrogenation : Destroys bacterial endotoxin on glassware and other heat-stable items, typically at about 250 ∘ C 250^\circ\text{C} 25 0 ∘ C . The cycle must be shown, initially and then at least annually, to achieve at least a 3-log endotoxin reduction using Endotoxin Challenge Vials (ECVs).